Solving the 'Parking' Problem in the Drug Monopoly Game

The Hill (December 2019)

3 Pages Posted: 2 Jun 2020

Date Written: December 27, 2019


Drug prices are too high. One reason is that brand-name drug firms delay generic entry. Another is that generic companies themselves delay entering the market. And they delay not only their entry but those of other generics as well.

Congress is considering addressing this “parking” of generic exclusivity. One proposal, the BLOCKING Act of 2019, would not solve the problem. Another, the Expanding Access to Low-Cost Generics Act, co-sponsored by Senators Smith and Braun, would. This op ed explains how.

Keywords: settlements, generics, Hatch-Waxman Act

JEL Classification: I18, K21, L40, L41, L43, L65, O34, O38

Suggested Citation

Carrier, Michael A., Solving the 'Parking' Problem in the Drug Monopoly Game (December 27, 2019). The Hill (December 2019), Available at SSRN:

Michael A. Carrier (Contact Author)

Rutgers Law School ( email )

217 North Fifth Street
Camden, NJ 08102-1203
United States
856-225-6380 (Phone)
856-225-6516 (Fax)

Here is the Coronavirus
related research on SSRN

Paper statistics

Abstract Views
PlumX Metrics